Long-term diabetes treatment studied in relation to cancer outcomes

Date:

Share this article:

Del denne artikel:

New research is examining whether long-term use of the diabetes drug metformin is linked to differences in cancer risk, without suggesting it as a treatment.

In a large multi-centre study published in 2025, researchers observed that people with type 2 diabetes who had used metformin long term were diagnosed with certain cancers less often than patients treated with other diabetes medications.

The finding did not claim prevention, but it was enough to revive an ongoing scientific debate.

A study that reopened the question

The Times of India reported on several observational studies indexed in PubMed Central showing lower rates of colorectal and liver cancer among long-term metformin users.

Similar patterns have appeared in earlier datasets, but the scale of the 2025 analysis brought renewed attention.

Also read: Several children and adults affected by fungal infection in local community

Researchers stressed that the results show association rather than direct cause. Still, the consistency has raised a key question: why does metformin keep appearing in cancer-related research when many other diabetes drugs do not?

Why metformin stands apart

Metformin differs from insulin and some newer glucose-lowering treatments because it does not increase insulin levels.

Instead, it reduces glucose production in the liver and improves insulin sensitivity. High insulin levels are known to stimulate cell growth, a process that cancer can exploit.

This distinction has made metformin especially interesting as cancer research increasingly focuses on metabolism and inflammation rather than single, targeted compounds.

Also read: Long-term alcohol consumption significantly increases cancer risk

Overlapping biology, clear limits

Type 2 diabetes and cancer share biological pathways, including chronic inflammation, obesity and altered energy use in cells.

Metformin appears to interact with these processes, potentially reducing conditions that support tumour growth.

Experts caution that metformin is not a cancer drug and should not be used for prevention outside diabetes care.

Clinical trials are now testing whether it could play a supportive role alongside standard cancer treatments. Until then, established measures like healthy weight, physical activity and screening remain central.

Also read: New study: Chemicals found in bottled water

Sources: The Times of India and Pubmed

Also read: New research: Air pollution increases the risk of ALS

This article is made and published by Mie Hermansen, who may have used AI in the preparation.

Other articles

Creatinine levels by age and sex: what your blood test number means

The lab number most people see first tells only half the kidney story.

How eating ginger every day can affect your blood pressure and joints

A new NIH-listed meta-analysis puts a number on the daily-ginger habit.

GLP-1 drugs like Ozempic may now be an option for a group of patients long left out

The 2026 American Diabetes Association guidance opens GLP-1 therapy to a new patient group.

Your gut bacteria may spread to the people around you more easily than anyone realized

A new Nature study finds gut microbes spread between people, sometimes across continents, faster than expected.

Creatinine levels by age and sex: what your blood test number means

The lab number most people see first tells only half the kidney story.

How eating ginger every day can affect your blood pressure and joints

A new NIH-listed meta-analysis puts a number on the daily-ginger habit.

GLP-1 drugs like Ozempic may now be an option for a group of patients long left out

The 2026 American Diabetes Association guidance opens GLP-1 therapy to a new patient group.